Why the study?
It was unknown whether digitoxin reduces all-cause mortality or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care.
Does digitoxin reduce the risk for all-cause mortality and/or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care treatment?
Does digitoxin reduce the risk for all-cause mortality and/or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care treatment?
The DIGIT-HF trial is designed to evaluate whether the addition of digitoxin to standard of care improves clinical outcomes in patients with advanced chronic HFrEF.
May guide digitoxin add-on therapy in advanced HFrEF; extends limited modern RCT data on cardiac glycosides.
The DIGIT-HF trial will provide important evidence, whether the cardiac glycoside digitoxin reduces the risk for all-cause mortality and/or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care treatment.
No takes yet. Share an insight, caveat, or question.
Bavendiek et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: